Study of therapeutic effect of sitaglipti
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19 ,virus identifiedu07.1
- Registration Number
- IRCT20200420047147N2
- Lead Sponsor
- Artesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Patients who have been diagnosed with Covid 19 based on CT scan or PCR.
Patients with fasting blood sugar above 100 at the time of referral
Patients with previous diagnosis of diabetes and under treatment
Study and accept consent to participate in the study
Patients over 18 years of age
Exclusion Criteria
Acute renal failure, chronic renal failure with stage 4,5
Acute and chronic liver failure
History of immunodeficiency diseases, using immunodeficiency drugs
Pregnancy and breastfeeding
Patients who are admitted to the intensive care unit upon arrival
Patients with contraindications to cytagliptin (pancreatitis and its history, diabetic gastroparesis, history of severe drug allergy)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method O2 saturation without mask. Timepoint: Daily. Method of measurement: Thermometer.;Fasting blood suger. Timepoint: Daily, From admission to discharge time. Method of measurement: Glucometer.;Covid-19 infection. Timepoint: At the beginning of the hospital admission. Method of measurement: Covid RT-PCR test.;Disease severity. Timepoint: At the beginning and end of intervention. Method of measurement: Based on protocol and clinical symptoms.;Cbc diff. Timepoint: every other day in between from the beginning of hospitalization until discharge. Method of measurement: labratory.
- Secondary Outcome Measures
Name Time Method Hospitalization duration. Timepoint: discharge time. Method of measurement: clinical record.;Death. Timepoint: at the end of study. Method of measurement: medical record.